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Abstract
Sickle Cell Disease and ß-thalassemia, which are caused by defective or deficient adult ß-
globin (HBB) respectively, are the most common serious genetic blood diseases in the
world. Persistent expression of the fetal ß-like globin, also known as γ-globin, can ameliorate
both disorders by serving in place of the adult ß-globin as a part of the fetal hemoglobin tet-
ramer (HbF). Here we use CRISPR-Cas9 gene editing to explore a potential γ-globin
silencer region upstream of the δ-globin gene identified by comparison of naturally-occurring
deletion mutations associated with up-regulated γ-globin. We find that deletion of a 1.7 kb
consensus element or select 350 bp sub-regions from bulk populations of cells increases
levels of HbF. Screening of individual sgRNAs in one sub-region revealed three single
guides that caused increases in γ-globin expression. Deletion of the 1.7 kb region in
HUDEP-2 clonal sublines, and in colonies derived from CD34+ hematopoietic stem/progeni-
tor cells (HSPCs), does not cause significant up-regulation of γ-globin. These data suggest
that the 1.7 kb region is not an autonomous γ-globin silencer, and thus by itself is not a suit-
able therapeutic target for gene editing treatment of ß-hemoglobinopathies.
Introduction
The ß-hemoglobinopathies Sickle Cell Disease (SCD) and ß-thalassemia are genetic blood dis-
eases characterized by defective or deficient adult ß-globin (HBB). SCD is a monogenic reces-
sive disorder caused by a single-nucleotide mutation in HBB. SCD affects at least 90,000
predominantly African-American individuals in the US and millions more worldwide, pre-
dominantly in Africa and Southern India [1–3]. Even in the developed world individuals with
SCD experience a greatly reduced quality of life, and suffer an ~30-year decrement in lifespan
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[4]. ß-thalassemia is characterized by reduced or absent expression of HBB. The disease affects
hundreds of thousands worldwide, with approximately 23,000 births annually in its most severe
form, transfusion-dependent ß-thalassemia [5]. The disease is often managed with chronic
blood transfusions, which eventually leads to iron overload requiring chelation therapy. Cur-
rently the only cure for both SCD and ß-thalassemia is allogeneic stem cell transplantation [6].
Both SCD and transfusion-dependent ß-thalassemia can be ameliorated by increased
expression of γ-globin. γ-globin is a ß-like globin that, along with α-globin, comprises hetero-
tetrametric fetal hemoglobin (HbF) [7]. HbF inhibits polymerization of sickle hemoglobin
(HbS), and levels of HbF above ~20% are associated with a virtual absence of manifestations of
SCD and ß-thalassemia. Increased HbF in adults is a positive predictor of survival in patients
with SCD [4,8]. In ß-thalassemia, expression of γ-globincan replace the function of deficient
ß-globin. Thus, methods to elevate expression γ-globinare of considerable therapeutic interest.
CRISPR-Cas9 is a gene editing technology that enables efficient and facile genome manipu-
lation via targeted generation of a double strand break (DSB) [9,10]. The break is repaired
through either of two general pathways: error-prone non-homologous end joining (NHEJ), or
accurate homology-directed repair (HDR) [11,12]. Targeting is directed by a 20 nucleotide
guide RNA (gRNA) bound by Cas9 and a Protospacer Adjacent Motif (PAM) within the
genome [10]. The development of this modular, user-friendly targeting system has led to an
explosion of interest in gene editing, including for the treatment of the hemoglobinopathies.
Strategies to drive -globin expression in erythroid cells via ex vivo gene editing of hemato-
poietic stem/progenitor cells (HSPCs) have recently emerged [13]. Decreased expression of
BCL11A, which encodes transcription factor that is necessary for silencing of γ-globin expres-
sion in adult-stage erythrocytes [7,14], leads to high-level expression of γ-globin. Other efforts
have targeted the ß-like globin locus, reproducing naturally occurring HPFH mutations in the
promoters of the two γ-globin genes, either through precise genome editing [15,16], or
through NHEJ-mediated indel formation to disrupt transcription factor binding sites entirely
[17–19].
We used gene editing to explore a potential approach to create an HPFH phenotype. We
compared naturally-occurring deletions causing either HPFH or ß-thalassemia identified a
candidate 1.7 kb intergenic repressor region upstream of the HBD gene [20] (Figure a in S1
File). We found that CRISPR-Cas9 deletion of this region and specific sub-regions induced
expression of HbF in heterogeneous pools of HUDEP-2 cells. However, multiple clonal
HUDEP-2 sublines harboring a deletion of the 1.7 kb region did not exhibit increased HbF.
We also observed little up-regulation of γ-globin expression when the deletions were made in
CD34+ hematopoietic stem and progenitor cells (HSPCs), after differentiation into erythroid
colonies and erythroblasts. These results suggest that this 1.7 kb region may contribute to
developmental silencing of γ-globin but is not an autonomous γ-globin silencer.
Results
Defining a minimal HBG-HBD intergenic region associated with γ-globin
silencing
We began by examining breakpoints of naturally-occurring HPFH deletions to define a mini-
mal region upstream of HBD whose deletion is associated with increased γ-globin expression.
Individuals lacking the intergenic region between the δ-globin (HBD) and γ-globin (HBG1
and HBG2) genes exhibit an HPFH phenotype, in particular the 7.2 kb “Corfu” deletion [21]
and several more extended deletions including HPFH-1 and the French HPFH deletion
[18,22]. In contrast, deletions that do not include this region are not associated with high HbF
expression and instead cause ß-thalassemia [20]. Both HPFH deletion mutations and ß-
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thalassemia deletions include ß-globin. We hypothesized that these two effects, induction of γ-
globin and deletion of ß-globin, were spatially distinct and separable: deletion of regions asso-
ciated with HPFH can independently up-regulate γ-globin even in the presence of an intact ß-
globin gene. We used the HbVar database [23] to identify an exact 1.72 kb genomic region
between the 5’ breakpoint of the French HPFH deletion and the Macedonian δ/ß-thalassemia
deletion (Figure a in S1 File). This region also appeared to harbor a binding site for Bcl11a in a
ChIP-Seq analysis [20]. Hereon we refer to this 1.7 kb region as the Putative Repressor Region,
or “PRR” (Fig 1A). The small size of the PRR makes it attractive for genetic dissection, unlike
larger deletions [18,19,24]. We sought to explore the relationship between PRR deletion geno-
types and globin expression phenotypes.
Up-regulation of fetal hemoglobin in heterogeneous pools of edited
HUDEP-2 cells
As a model system to assess γ-globin expression we used the recently-developed HUDEP-2
cell line, which can be differentiated into late-stage erythroblasts [25]. These cells display an
adult pattern of globin expression, with ß-globin expressed and γ-globin silenced. HUDEP-2s
can express γ-globin after various genetic manipulations in cis or trans to the ß-globin locus,
and have been used to explore genotype-phenotype relationships related to globin switching
[17,26,27]. To edit HUDEP-2 cells, we used Cas9 RNP electroporation, which we have found
to be effective at gene targeting in cell lines and CD34+ HSPCs [28–30]. Our goal was to genet-
ically dissect the PRR to identify small regions whose deletion would activate γ-globin, and by
extension HbF, expression. We designed Cas9 RNPs and Cas9 RNP pairs to target progres-
sively smaller regions, starting with the full PRR, moving to overlapping sub-regions of the
PRR, and culminating in individual Cas9 RNP electroporation of a single sub-region.
We generated Cas9 RNP pairs that cut at the 5’ and 3’ ends of the PRR, and the naturally
occurring Corfu deletion (Fig 1B and Figure b in S1 File, guides in Table c in S1 File [21]).
Electroporation with pairs of RNPs in this manner can lead to deletion of the intervening
sequence, and has been used to reproduce naturally-occurring mutations in earlier studies
[18]. Efficient editing by individual candidate guide RNAs was assayed with T7 endonuclease I
(T7E1) digest, and guides with>50% editing at each end were paired (Figure b in S1 File).
Deletion of the PRR or Corfu region in cell pools was confirmed by the presence of a shorter
DNA fragment on an agarose gel following PCR amplification of the targeted regions (Fig 1C).
Pools of HUDEP-2 cells electroporated with these pairs of deletion-forming Cas9 RNPs were
differentiated into erythrocytes to assess HbF expression by intracellular flow cytometry with
an HbF-specific antibody. The edited cell pools displayed an increased proportion of cells
expressing HbF (Fig 2A, and Figure b in S1 File) [31]. 17.2% of cells expressed HbF when the
PRR deletion RNPs were delivered, and 23% of cells expressed HbF when the Corfu deletion
RNPs were delivered, compared to 1.9% of cells for untreated cells.
We further interrogated the PRR by dividing it into 9 overlapping sub-regions and targeting
each sub-region separately. In an attempt to enhance deletion, we designed 150 nucleotide sin-
gle strand oligonucleotide donors (ssODNs) for HDR. These ssODNs had one half matching
75 bp upstream of one breakpoint, and the other half matching 75 bp downstream of the other
breakpoint, and thus corresponding to the sequence of a deleted allele (Fig 2B, Table c in S1
File). It is possible that these ssODNs may increase the likelihood that the dual DSBs generated
by two RNPs are resolved in favor of a precise deletion, although this hypothesis was not tested
in this study (Fig 2B). We evaluated guides by T7E1 digest of genomic DNA. Cultures of
HUDEP-2 cells were treated with each pair and the appropriate stapler ssODN and then differ-
entiated. Of each RNP/ssODN set, those programming deletion of regions 4 and 9 were
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associated with a significant increase in the frequency of HbF-positive cells by flow cytometry,
increasing expression by 7% above the mean (of all cultures) for region 4, and 6.5% for region
9 (Fig 2C). RNPs that delete regions that overlap regions 4 and 9 also led to an increase in
HbF-expressing cell frequency. Based on these observations, we focused our subsequent stud-
ies on region 4, which was the sub-region associated with the largest increase in fetal hemoglo-
bin expression. Note that these screening studies did not definitively establish a link between
deletion of any region and an increase in HbF expression.













































Fig 1. Targeted deletion of genomic regions implicated in γ-globin silencing using selection-free Cas9 RNP
electroporation. A) Schematic depicting two targeted regions: the naturally-occurring Corfu HPFH deletion and the
1.7 kb putative repressor region (PRR) upstream of HBD, with the 2 pairs of cuts attempted shown (13). B) PCR
amplification after gene editing with pairs of Cas9 RNPs that delete the Corfu and PRR regions with primers outside
the targeted regions. Deletion is indicated by the presence of bands with greater mobility corresponding to the deleted
alleles which give rise to shorter PCR products.
https://doi.org/10.1371/journal.pone.0208237.g001
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Deletion of genomic elements using pairs of Cas9 RNPs is useful for defining regions of
phenotypic interest. However, two DSBs in one targeted cell could be resolved to a variety of
genotypes besides simple deletion: inversions, duplications, and short insertions or deletions
at either cut site [19,32]. To avoid these complications, a single cut site is preferred. Hence we
attempted to identify a single gRNA within the PRR sub-region 4 that could induce a signifi-
cant increase in HbF expression. We synthesized 20 Cas9 RNPs to target every wild-type Cas9
PAM within sub-region 4 (Fig 2D and Table c in S1 File). We introduced each of these RNPs
individually to HUDEP-2 cells by electroporation in biological triplicate. Gene editing by these
RNPs was confirmed by T7 endonuclease I digest (Figure c in S1 File). All but two RNPs (cut-
ting at -5 and 21 bp from the 5’ breakpoint of region 4) led to indel formation within sub-
region 4. and analyzed HbF using intracellular flow cytometry. After differentiation into eryth-
rocytes, we found that three RNPs yielded modest but statistically significant increases in the
frequency of HbF-expressing cells, when compared to a non-targeting control RNP (Fig 2D).
Gene edited HUDEP-2 clonal cell lines lacking the PRR or two of its
subregions do not consistently up-regulate HbF
We next sought to relate loss of one or more regions within the PRR to γ-globin (and by exten-
sion HbF) expression. Our results suggested that the full PRR and discrete sites within it may
be involved in silencing of γ-globin in HUDEP-2 cells. However, a given RNP pair can gener-
ate many alleles: translocations, inversions, or indel mutations at either cut site. Results from
gene-edited polyclonal pools cannot distinguish between these, and so do not clearly show
whether a region is required for γ-globin silencing. Indeed, we found evidence of short indel
(but not inversion) genotypes when we used amplicon next generation sequencing (NGS) to
genotype edited cell clones isolated from these pools (Table b in S1 File), but did not find evi-
dence of long deletions, as has been reported elsewhere [33]. We therefore examined detailed
genotype-phenotype relationships through generation and evaluation of edited HUDEP-2
derived clonal cell lines targeting either the PRR or sub-regions 4 or 9.
HUDEP-2 cells are a polyclonal pool of erythroblasts immortalized by lentiviral transduc-
tion [25]. We first subcloned HUDEP-2, and selected one clone that retained differentiation
and hemoglobinization capabilities, henceforth termed “H2.1”. This and the parental
HUDEP-2 cell line were used in subsequent studies.
We delivered PRR deletion RNP pairs to a HUDEP-2 pool and to H2.1, isolated edited
clones by limiting dilution, and genotyped the resulting clonal lines by PCR amplification and
multiplexed next-generation amplicon sequencing (Table a in S1 File). We obtained multiple
heterozygous and homozygous deletion clones derived from both HUDEP-2 pool and and the
H2.1 subclone (Table a in S1 File). We differentiated several sets of these clones into erythro-
blasts and assessed globin expression by flow cytometry for HbF-expressing cells and HPLC
Fig 2. Interrogation of the PRR in the parent HUDEP-2 cell line. A) Representative intracellular FACS plots showing a
population of HbF-expressing HUDEP-2 cells, after electroporation of RNP pairs generating each deletion and differentiation
into erythrocytes. B) Schematic depicting the PRR, divided into 9 overlapping sub-regions. Deletion of each sub-region is
programmed by a pair of RNPs. Sub-region deletions leading to statistically significant increase in HbF expression are marked in
red. C) Flow cytometry enumeration of HbF-expressing HUDEP-2 cells after introduction of Cas9 RNPs driving deletion of each
sub-region, before and after differentiation into erythroblasts. Results are (mean of each culture)-(mean of all cultures) ± s.d. for 3
biological replicates, regions 4 and 9 (in red) deletion led to a statistically significant increase in HbF expressing cells, compared to
the mean of all cultures. D) Scanning mutagenesis screen using 20 separate Cas9 RNPs targeting every PAM in region 4 to
differentiated HUDEP-2 cells, with HbF-expressing cells enumerated by flow cytometry. Each RNP is denoted by its cut site
within the PRR region 4, from -4 (4 nt upstream of the 5’ region breakpoint) to 376 (376 nt downstream of the 5’ region
breakpoint). To ensure consistency, synthetic RNAs were used. Results are mean ± s.d. for 3 biological replicates. Statistically
significant sites are marked in red.
https://doi.org/10.1371/journal.pone.0208237.g002
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for hemoglobin expression. While homozygous deletion of the PRR increased HbF expression
in a flow cytometry assay in some of the clones, other clones showed no increase in HbF
expression (Fig 3A). By HPLC assay, deletion of the PRR in select clones derived from
HUDEP-2 failed to induce HbF at all (Fig 3B). This is in stark contrast to the results we
obtained from deleting the same region in cell pools. These results suggest that deletion of the




































































































































































































































































































































































Fig 3. Interrogation of HUDEP-2 and H2.1 cell clones carrying deletions of the PRR and selected sub-regions. A) Proportion of HbF-expressing cells
assayed by flow cytometry in cell clones carrying the indicated PRR deletions (mean ± s.d. of 3 biological replicates). B) Quantitation of HbF expression
by HPLC in selected clones carrying the indicated PRR deletions, (mean ± s.d. of 3 technical replicates). No significant differences in HbF expression
were seen in comparison to parent HUDEP-2 cells. C) Expression of HbF in clonal cell lines carrying the indicated sub-region deletions, measured by
flow cytometry, error bars represent mean ± s.d. of 2–8 independently-derived clones for each genotype. Clones with statistically significant differences
in HbF-expressing cells compared to unedited H2.1 cells are noted (unpaired t-test). D) Expression of HbF in selected clonal cell lines carrying the
indicated sub-region deletions, measured by hemoglobin HPLC Each bar represents the mean ± s.d. of 3 technical replicates for each clone. Phenotypic
information for each clone is in Table a in S1 File.
https://doi.org/10.1371/journal.pone.0208237.g003
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We also generated clonal cells with deletions of the two candidate sub-regions of the PRR
(4 and 9) identified by screening in the parent HUDEP-2 line (Figure d in S1 File), editing
both HUDEP-2 (sub-region 4 and 9) and H2.1 (for sub-region 4 only). Deletions were con-
firmed by next-generation sequencing of a PCR amplicon encompassing the full PRR (Table a
in S1 File, and supplementary material). We obtained 8 homozygous deletion and 9 heterozy-
gous deletion clones of region 4 in HUDEP-2, 2 homozygous and 7 heterozygous deletion
clones of region 4 in H2.1, and 3 homozygous and 2 heterozygous deletion clones of region 9
in HUDEP-2. We note that even in most “homozygous” clonal cell lines, two distinct geno-
types are often seen, as the deleted regions vary by 1–10 bp (Table a in S1 File). In all 32 of the
37 clonal cell lines have two distinct genotypes, suggesting these lines are accurately genotyped
(HUDEP-2 cells are diploid). We saw no evidence of any unexpected large deletions in any cell
line within the 2.5 kb region analyzed by next-generation sequencing [33]. After derivation,
clonal cell lines were differentiated into erythroblasts, and HbF-expressing cells were counted
by flow cytometry (Fig 3C). Some clones homozygous for sub-region 4 deletion exhibited
increased proportion of HbF-expressing cells (with up to 40% for cells derived from HUDEP-
2, but not for lines from H2.1, Fig 3C). However, other deletion clones did not exhibit any
apparent increase in HbF. Overall, we observed large variation in HbF-expressing cells
between clonal cell lines with the same genotype, whether derived from the polyclonal
HUDEP-2 line or the isogenic H2.1 sub-clone.
We used HPLC to measure globin content in erythroid cell differentiated from edited
HUDEP-2 and H.2 clones (Fig 3D, traces in Figure e in S1 File). Two HUDEP-2 derived clones
with homozygous knockouts in sub-region 4 exhibited variable proportions of HbF (1.67% to
98.7%, average 41.8%). But heterozygous sub-region 4 deletion clones showed no increase in
HbF, nor did any H2.1-derived clones with homozygous knockouts in sub-region 4. Our
results highlight significant clonal differences in HbF expression between sub-clones of
HUDEP-2 cells, since H.21 is itself a sub-clone of HUDEP-2. Taken together, our data also
suggest that sub-regions 4 and 9 of the PRR are not autonomous silencers of γ-globin silencing
in HUDEP-2 cells, since homozygous deletions of these regions leads to increased HbF expres-
sion in cell pools but variable expression between edited clonal cell lines.
Deletion of PRR or two PRR sub-regions in erythroid colonies derived from CD34+
HSPC does not up-regulate HbF. Finally, we assessed whether some PRR or PRR sub-
region deletion genotypes can alter γ-globin expression in erythroid colonies derived from
human primary CD34+ HSPCs. We edited adult human CD34+ HSPCs with Cas9 RNPs
pairs targeting either the PRR, sub-region 4 or sub-region 9 [28] and plated the cells sparsely
in methocellulose to form clonal colonies (CFUs). We picked erythroid colonies (both
BFU-E and CFU-E), genotyped each colony using PCR and amplicon NGS, and determined
globin gene expression using RNA-seq (Fig 4A) [18]. We used pairs of Cas9 RNPs to target
deletion of three regions: the full 1.7 kb PRR, sub-region 4, and sub-region 9. ß-globin
(HBB) expression ranged from 23% to 50% of globin transcripts but was not significantly
altered between unedited cells and PRR homozygous knockouts, sub-region four heterozy-
gous or homozygous knockouts, and sub-region nine heterozygous or homozygous knock-
outs. (Fig 4B and Table b in S1 File). γ-globin (HBG1+HBG2) expression was variable
between clonal erythroid colonies and ranged from 0.5% to 26% of globin transcripts (Fig
4C and Table b in S1 File). There was no clear association between PRR deletion genotype
and γ-globin expression: homozygous deletion of sub-region 9 did not affect γ-globin
expression, while heterozygous deletion may have, and vice versa for deletion of sub-region
4. No deletion genotype led to a statistically-significant increase in γ-globin expression
compared to unedited colonies. Any increase in γ-globin expression is obscured by the high
variation between colonies, and does not reach therapeutic levels. To confirm whether
CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells
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variation between clones masked the effects of PRR deletion, we differentiated unselected
pools of CD34+ HSPC in erythroblasts following editing with either PRR-editing RNP pairs
or a non-targeting control guide against BFP (Figure f in S1 File). γ-globin mRNA ranged
from 1.5% of globin transcripts on average (control) to 2.8% (PRR deletion). These results
suggest that neither the full PRR nor either of the selected sub-regions are in and of them-




















































































































Fig 4. Genotype-phenotype relationships in clonal BFU-E colonies derived from edited hematopoietic stem/progenitor cells. A) Workflow depicting
erythroid colony (BFU-E) formation genotype/phenotype assay using edited HSPC. HSPC were edited using RNPs targeting the desired region, plated in
methocult, and colonies were grown for 14 days. Erythroid colonies were picked and genotyped by next-generation sequencing and phenotyped for their
globin gene expression profile using RNA-seq. B) ß-globin (HBB) expression in erythroid colonies after gene editing, determined by RNA-seq. There was
no statistically-significant difference in expression between each genotype of colony. C) γ-globin (HBG1+HBG2) expression in erythroid colonies after
gene editing, determined by RNA-seq. Because of the high variation between colonies of the same genotype, there was no statistically-significant
difference in expression between each genotype of colony. To control for effects of RNP electroporation, the unedited cells were electroporated with a
non-targeting RNP against BFP.
https://doi.org/10.1371/journal.pone.0208237.g004
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Discussion
Here we explored a potential approach to activate expression of γ-globin in adult erythroid
cells via targeted ablation of a 1.7 kb potential repressor region (PRR) upstream of HBD. We
identified the PRR from analysis of naturally occurring human genotypes that lead to HPFH
(Figure a in S1 File) [20]. In bulk populations of the HUDEP-2 polyclonal cell line we found
that deletion of the PRR and smaller sub-regions led to γ-globin re-expression. However, we
found that edited HUDEP-2 clones or edited erythroid colonies derived from CD34+ HSPCs
were not consistently associated with increased γ-globin expression. Instead, we found marked
heterogeneity in γ-globin expression between clones (or clonal colonies) of the same genotype
(and ultimately isolated from the same individual), including among wild-type sub-clones and
clonal colonies. We conclude that deletion of the PRR alone is not sufficient for up-regulation
of γ-globin to therapeutic levels.
The possibility remains that the PRR cooperates with other regions within or downstream
of HBB to mediate γ-globin silencing. Previous studies have shown that deletions including
both the PRR and all or part of ß-globin gene, along with other downstream elements, can
induce γ-globin [18,19]. In this scenario, γ-globin expression is dependent on both ß-globin
loss and loss of the PRR. However the efficient induction of more extended deletions encom-
passing both the PRR and the ß-globin gene may be more challenging in a clinical setting.
The region containing the PRR was implicated in γ-globin silencing on the basis of two
lines of evidence. One was the comparison of multiple large deletions in the ß-globin locus:
large deletions that do not include the PRR cause ß-thalassemia, while other deletions that do
include this region confer a more benign HPFH phenotype [18,20,22]. The second was a
ChIP-chip analysis that identified binding of Bcl11a within the PRR [20]. Bcl11a is well docu-
mented as a regulator of developmental γ-globin silencing [34], and so this result seemed con-
sistent with the idea that the region was required for developmental silencing. However a
more recent study that used an orthogonal method to map Bcl11a binding sites did not iden-
tify a binding within the PRR [35].
The broad variation in HbF expression we observed between wildtype HUDEP-2 derived
subclones and among wild-type erythroid colonies in HSPC suggests that γ-globin expression
level is prone to large spontaneous changes even in cell lines or colonies derived from cells
with the same genotype. This suggests that caution should be used in interpreting selected
results from HUDEP-2 subclones or HSPC colonies. It is not clear why this is the case, nor
why there was a trend indicating that functional elements resided sub-regions 4 and 9 and
their overlapping neighbors. Dual guide editing using Cas9 has the potential to generate com-
plex genotypes, including inversions, although no inversions were seen in our NGS analysis
[19,32]; it is possible that a minority of these events had an outsize effect in edited pools of
cells. A recent study suggested that large deletions and other rearrangements may occur fol-
lowing editing with a single guide, although we do not see direct evidence for this in our NGS
analysis, which utilized a 2.5 kb PCR amplicon [33]. Our investigation of clonal cell lines and
clonal colonies focused on frank deletion genotypes, and it is possible that more complex
genotypes led to γ-globin re-expression in subsets within edited pools of cells, although we saw
no evidence of these genotypes in our NGS data. Regardless, our study suggests that the PRR is
not an autonomous γ-globin silencer.
While this manuscript was in preparation a new study exploring deletions of larger geno-
mic regions encompassing the PRR was reported using similar methods [19]. Interestingly,
deletion of the 7.2 kb Corfu region or a 3.5 kb region that included the 1.7 kb PRR did not lead
to significant fetal hemoglobin re-expression in HUDEP-2 cells. Instead a much larger 13.2 kb
deletion that encompassed the adult ß-globin promotor did lead to robust γ-globin expression.
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However, this large deletion also led to 3-fold drop in ß-globin expression, similar to the
HPFH-1 deletion using CRISPR/Cas9 in HSPCs [18]. These results and others suggest that
simultaneous deletion of the PRR and disruption of ß-globin expression may synergize to lead
to high levels of γ-globin re-expression.
Materials and methods
HUDEP-2 Cells and cell culture
HUDEP-2 cells were cultured and differentiated according to published protocols [25], with
the exception that doxycycline was included in both differentiation and expansion media.
Expansion medium: 1 μM dexamethasone, 1 μg/mL doxycycline, 50 ng/mL stem cell factor
(Peprotech, Inc.), 5 U/mL EPO (Amgen, pharmaceutical grade), in SFEM medium (Stem Cell
Technologies). Differentiation medium: 5% human serum (Sigma Aldrich), 2 IU/mL heparin
(Sigma Aldrich), 10 μg/mL Insulin (Sigma Aldrich), 5 U/mL EPO (Amgen), 500 μg/mL holo-
transferrin (Sigma Aldrich), 1 μM mifepristone (Sigma Aldrich), 1 μg/mL doxycycline in
IMDM media (with Glutamax, Gibco, Inc.). Differentiation medium was prepared with one
week of use and sterile-filtered using a 0.22 μm filter. To differentiate HUDEP-2 and H2.1 cells
from expansion culture, cells were pelleted (300 x g, 5 minutes), thoroughly decanted, re-sus-
pended in differentiation medium at a density of<1,000,000 cells/mL, and cultured for 5 days
before analysis for hemoglobin expression by flow cytometry or HPLC.
Synthesis of Cas9 RNPs
Cas9 RNP component synthesis and assembly was carried out based on published work, and
are available online at https://www.protocols.io/groups/igi/protocols [28,36]. Cas9 was pre-
pared by the UC Berkeley Macro Lab using a published protocol [36]. Cas9 was stored and
diluted in sterile-filtered Cas9 Buffer (20 mM HEPES pH 7.5, 150 mM KCl, 1 mM MgCl2, 10%
glycerol, 1 mM TCEP). sgRNA was synthesized by assembly PCR and in vitro-transcription. A
T7 RNA polymerase substrate template was assembled by PCR from a variable 59 nt primer
containing T7 promotor, variable sgRNA guide sequence, and the first 15 nt of the non-vari-
able region of the sgRNA (T7FwdVar primers, 10 nM, Table c in S1 File), and an 83 nt primer
containing the reverse complement of the invariant region of the sgRNA (T7RevLong, 10
nM), along with amplification primers (T7FwdAmp, T7RevAmp, 200 nM each). Phusion
high-fidelity DNA polymerase was used for assembly (New England Biolabs, Inc.). Assembled
template was used without purification as a substrate for in vitro transcription by T7 RNA
polymerase using the HiScribe T7 High Yield RNA Synthesis kit (New England Biolabs, Inc.).
Resulting transcriptions reactions were treated with DNAse I, and purified either by with a 5X
volume of homemade SPRI beads (comparable to Beckman-Coulter AMPure beads), and
eluted in DEPC-treated water. sgRNA concentration was determined by fluorescence using
the Qubit RNA BR assay kit (Life Technologies, Inc). Cas9 RNP was assembled immediately
prior to electroporation of target cells (see below). To electroporate a 20μL cell suspension (see
below) with Cas9 RNP, a 3.75 μL solution containing a 1.2–1.3X molar excess of sgRNA in
Cas9 buffer was prepared. A 3.75 μL solution containing 75 pmol purified Cas9 in Cas9 buffer
was prepared and added to the sgRNA solution slowly over ~30 seconds, and incubated at
room temperature for >5 minutes prior to mixing with target cells. For electroporation with
pairs of Cas9 RNPs, half the amounts and volumes above were used to assemble RNPs, which
were then mixed after assembly. For studies depicted in Fig 2E (saturating mutagenesis of PRR
sub-region 4), RNA was generously provided by Synthego, Inc. For electroporation of HSPCs
(Fig 4), synthetic sgRNA was purchased from Synthego, Inc. Synthesis of RNPs from synthetic
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sgRNA was accomplished in an analogous manner, using stocks of dried RNA hydrated to
45 μM in water or 0.5X TE.
Electroporation of HUDEP-2 Cells with Cas9 RNP using the Lonza 4d
electroporator
HUDEP-2 cells were cultured in expansion medium prior to editing to mid-log phase
(200,000–1 million cells per mL of culture). To electroporate, 100,000–200,000 cells were spun
at 300xg for 5 minutes, and resuspended in 20 μL of Lonza P3 solution and 7.5 μL of Cas9
RNP solution prepared as described above, before transfer of the entire 27.5 μL mixture to a
small-scale Lonza S electroporation cuvette. Cells were electroporated using Lonza 4d code
DD100. Cells were cultured a minimum of 2 days before differentiation and phenotyping
analysis.
Generation of clonal HUDEP-2 sublines
Gene-edited HUDEP-2 and H2.1 cells were cloned by limiting dilution into 96 well plates.
After ~2 weeks the cultures were passaged and half of the cells were removed for DNA
extraction and PCR (see above). Genotyping was initially performed with standard PCR
and agarose gel electrophoresis using primers for the indicated deletion (Table c in S1 File).
Clones with desired genotypes by PCR were confirmed with next-generation sequencing
(see below).
Assay of HbF-positive HUDEP-2 cells by intracellular flow cytometry
FACS for HbF was adapted from existing protocols [26]. Differentiated or undifferentiated
HUDEP-2 cells were pelleted by centrifugation at 500 x g for 5 minutes, washed with PBS/
0.1% BSA, pelleted again and resuspended in 200 μL 0.05% glutaraldehyde (freshly prepared
from evacuated ampules of 20% glutaraldehyde from Sigma Aldrich) in PBS and incubated for
10 minutes to fix the cells. Cells were pelleted at 600 x g for 5 minutes and resuspended in
200 μL of 0.1% Triton X-100 in PBS/0.1% BSA and incubated for 10 minutes to permeabilize
cells, and pelleted at 600 x g once again before resuspension in 50 μL of anti-fetal hemoglobin-
FITC antibody at a 1–10 dilution in PBS/0.1% BSA (BD Biosciences, Inc. clone 2D12) and
incubated for 20 minutes to stain cells. After staining, cells were washed three times in PBS/
0.1% BSA before analysis by flow cytometry.
Quantification of relative hemoglobin expression with HPLC
HPLC analysis for hemoglobin expression in differentiated cells was run essentially as
described in previous work [37]. Hemolysates for HPLC were prepared from 1–5 million dif-
ferentiated cells pelleted and resuspended at 100,000 cells/μL in hemolysate reagent (Helena
Laboratories), incubated for 10 minutes at room temperature, and clarified by centrifugation.
10 μL of lysate was applied to the HPLC column for hemoglobin analysis. For HPLC a Poly-
CAT A column 3.54 (PolyLC, Inc.) was used with mobile phase A for loading (20 mM Bis-tris,
2 mM NaCN, pH6.8) and B for elution (20 mM Bis-tris, 2 mM NaCN, 200 mM NaCl, pH 6.9),
flow-rate 1.5 mL/min, and detection of hemoglobin by absorbance at 415 nm, and gradient
from 0% to 100% mobile phase B over 30 minutes to separate hemoglobins. Hemoglobins
were identified based on mobility using a separate FASC hemoglobin standard (Trinity
biotech).
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Electroporation of CD34+ HSPCs with Cas9 RNPs
HSPC electroporation was as described [28]. CD34+ HSPCs (G-CSF mobilized, Allcells, Inc.)
were thawed and cultured in SFEM (StemCell Technologies, Inc.) with CC110 cytokines (Stem
Cell Technologies) for 2 days at a density of<500,000 cells/mL before editing. 100,000–
200,000 HSPCs were re-suspended in 20 μL of P3 solution and 7.5 μL of Cas9 RNP or RNP
pairs assembled as described above. Because ssDNA reduces viability when gene editing
HSPCs, no “stapler” ssDNAs were used to edit HSPCs. For HSPCs, only synthetic sgRNA was
used (Synthego, Inc.). HSPCs in P3 solution with RNP were electroporated using code ER100
on a Lonza 4d electroporator. After electroporation, cells were layered with 75 μL of SFEM
with CC110 and incubated for 5 minutes at room temperature before transfer to culture in
SFEM with CC110. Cells were cultured for 1 day before plating on MethoCult Express at 250
cells/well in a 6 well plate. A subset of the culture (~50,000 cells) was taken to confirm deletions
by PCR. After 14 days, individual BFU-E were picked and dispersed in 100 μL of PBS. Half of
the suspension was taken for genotyping by genomic PCR and next-generation sequencing,
and the other half was stored at -80. Colonies found to have the desired genotypes by genomic
DNA PCR were thawed and prepared for RNA-seq, and had their genotypes confirmed by
next-generation sequencing before completion of RNA-seq data analysis (see below).
RNA-seq of erythroid colonies
Total RNA was isolated from individual BFU-E with the ArrayPure Nano-scale RNA purifica-
tion kit (Epicentre), and converted into cDNA following the Smart-seq2 protocol [38]. The
cDNA was fragmented (median size of 170 bp) and ligated into Illumina sequencing libraries
with the KAPA HyperPlus kit (KAPA Biosystems). Libraries were sequenced on an Illumina
HiSeq4000 apparatus to produce single-ended reads of 50 nucleotides. Reads were aligned with
kallisto version 0.43.1 [39] against a reference sequence consisting of the main isoforms of each
globin gene at the α- and ß-globin loci. The following Ensembl transcript IDs were used:
ENST00000320868.9 (HBA1), ENST00000251595.10 (HBA2), ENST00000199708.2 (HBQ1),
ENST00000356815.3 (HBM), ENST00000354915.3 (HBZP1), ENST00000252951.2 (HBZ),
ENST00000335295.4 (HBB), ENST00000380299.3 (HDB), ENST00000454892.1 (HBBP1),
ENST00000330597.3 (HBG1), ENST00000336906.4 (HBG2), ENST00000292896.2 (HBE1).
Globin transcripts have high levels of sequence identity; to evaluate the ability of kallisto to
correctly assign a read to the transcript from which it was derived, we carried out simulations
using computationally generated 50-base reads. The globin transcripts listed above were mixed
in known proportions that simulate relative transcript levels in erythrocytes (HBA-1: 0.7, HBA-
2: 0.7, HBM: 0.01, HBB: 1.00, HBD: 0.04). HBG-1 and HBG-2 were varied between 0.005 and
0.10 to simulate the effect of varying levels of γ-globin expression in a mixture. Sequence seg-
ments of 50 nucleotides in length were sampled randomly from this mixture and from its
reverse complement (number of samples = 1,000,000), and aligned as described above. The ran-
dom sampling procedure was repeated 10 times for each mixture. For each alignment result, we
calculated the mean ratio of observed over expected counts for each transcript, which we used
as adjustment factors for the counts reported by kallisto after aligning real data; the difference
in transcript counts before and after adjustment ranged from -1% to 0.5%. The computed
adjustment factors were: HBA-1: 1.0397665108; HBA-2: 0.8890515518; HBM: 0.8195218055;
HBB: 1.0401825121; HBD: 1.1146242591; HBG-1: 1.321849175; HBG-2: 1.0079414563
T7 endonuclease assay
To select optimal gRNAs, genomic cutting using Cas9 RNPs was estimated using T7 endonu-
clease I assay. Genomic DNA was extracted from edited cells (HUDEP-2 or CD34+ HSPC)
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using QuickExtract solution (Epicentre, Inc.) to a density of>2,500 cells/μL. A PCR amplicon
of the targeted region was generated using GXL Primestar Polymerase (Takara, Inc.), 30 PCR
cycles, and manufacturer’s instructions, at a final volume of 50 μL using 5 μL of extracted
genomic DNA as template. 7 μL of unpurified PCR was mixed with water and 1X NEB buffer
2 to a final volume of 10 μL before re-annealing in a thermal cycler (95 degrees for 5 minutes,
cool to room temperature over 10 minutes). 1 μL of T7 endonuclease I was added (NEB, Inc.)
and reaction was digested for 30 minutes at 37˚C before visualization on a 2% agarose gel or
4–20% polyacrylamide TBE gel (Life Technologies, Inc.). Cutting was compared to PCR ampli-
cons from untreated cells.
Genotyping of HSPC colonies and HUDEP-2 clonal cell lines edited at the
PRR and sub-regions by PCR amplicon deep sequencing (NGS)
Genomic DNA preparation and PCR were performed identically as for T7 endonuclease digest
above, except that the PRR primers were used for all samples (see supplemental text for uned-
ited amplicon sequence). The 2.3 kb amplicon was purified, fragmented to an average length
of ~350 bp using a Covaris instrument, and prepared for NGS using the Illumina TruSeq
Nano HT kit. Libraries (1 for each colony or clonal cell line) were sequenced on an Illumina
MiSeq (2x300 paired-end sequencing). Demultiplexed and adaptor-trimmed reads were
aligned to the reference amplicon sequence, and the genotype determined by visual inspection
of aligned reads in IGV viewer software.
Supporting information
S1 File. Figures a-f Tables a-c, and Supplemental Information.
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